{"entity":{"type":"insider","cik":"0001249675","url":"/insider/0001249675","json_url":"/insider/0001249675.json","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":817,"n_filings":318,"first":"2003-08-08","last":"2025-11-13","span_basis":"filed_date"},"name_variants":[{"name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","source":"filing","n_filings":318,"first_seen":"2003-08-08","last_seen":"2025-11-13"}],"transactions":[{"id":4940944,"accession":"0001193125-25-280481","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-25-280481","line_url":"/filing/0001193125-25-280481","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive LS (A), LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31810.0,"shares_display":"31,810","price_per_share":3.9001,"price_display":"3.90","price_state":"stated","total_value":124062.181,"total_display":"124,062.18","total_whole":"124,062","shares_owned_after":124859.0,"shares_owned_after_display":"124,859","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-13","filed_date":"2025-11-13","scope":"insider","n_lines":2},{"id":4940881,"accession":"0001193125-25-280481","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-280481","line_url":"/filing/0001193125-25-280481","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive LS (A), LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8745.0,"shares_display":"8,745","price_per_share":4.0594,"price_display":"4.06","price_state":"stated","total_value":35499.453,"total_display":"35,499.45","total_whole":"35,499","shares_owned_after":153456.0,"shares_owned_after_display":"153,456","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-12","filed_date":"2025-11-13","scope":"insider","n_lines":2},{"id":4940858,"accession":"0001193125-25-280481","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-280481","line_url":"/filing/0001193125-25-280481","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive LS (A), LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5320.0,"shares_display":"5,320","price_per_share":4.3146,"price_display":"4.31","price_state":"stated","total_value":22953.672,"total_display":"22,953.67","total_whole":"22,954","shares_owned_after":161318.0,"shares_owned_after_display":"161,318","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-11","filed_date":"2025-11-13","scope":"insider","n_lines":2},{"id":4456529,"accession":"0001193125-25-274540","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-25-274540","line_url":"/filing/0001193125-25-274540","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive LS (A), LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18502.0,"shares_display":"18,502","price_per_share":4.5398,"price_display":"4.54","price_state":"stated","total_value":83995.3796,"total_display":"83,995.38","total_whole":"83,995","shares_owned_after":166101.0,"shares_owned_after_display":"166,101","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-10","filed_date":"2025-11-10","scope":"insider","n_lines":2},{"id":4456517,"accession":"0001193125-25-274540","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-274540","line_url":"/filing/0001193125-25-274540","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive LS (A), LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19739.0,"shares_display":"19,739","price_per_share":4.7467,"price_display":"4.75","price_state":"stated","total_value":93695.1113,"total_display":"93,695.11","total_whole":"93,695","shares_owned_after":182734.0,"shares_owned_after_display":"182,734","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-07","filed_date":"2025-11-10","scope":"insider","n_lines":2},{"id":4456510,"accession":"0001193125-25-274540","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-274540","line_url":"/filing/0001193125-25-274540","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Lyra Therapeutics, Inc.","issuer_ticker":"LYRA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive LS (A), LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32149.0,"shares_display":"32,149","price_per_share":5.1799,"price_display":"5.18","price_state":"stated","total_value":166528.6051,"total_display":"166,528.61","total_whole":"166,529","shares_owned_after":200480.0,"shares_owned_after_display":"200,480","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-06","filed_date":"2025-11-10","scope":"insider","n_lines":2},{"id":4165976,"accession":"0000950170-25-102537","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-102537","line_url":"/filing/0000950170-25-102537#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Orchestra BioMed Holdings, Inc.","issuer_ticker":"OBIO","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":700000.0,"shares_display":"700,000","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":1925000.0,"total_display":"1,925,000.00","total_whole":"1,925,000","shares_owned_after":5292556.0,"shares_owned_after_display":"5,292,556","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-01","filed_date":"2025-08-05","scope":"insider"},{"id":4197468,"accession":"0001062993-25-008341","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-25-008341","line_url":"/filing/0001062993-25-008341#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Acrivon Therapeutics, Inc.","issuer_ticker":"ACRV","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":298886.0,"shares_display":"298,886","price_per_share":1.34,"price_display":"1.34","price_state":"stated","total_value":400507.24,"total_display":"400,507.24","total_whole":"400,507","shares_owned_after":3104139.0,"shares_owned_after_display":"3,104,139","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-01","filed_date":"2025-05-01","scope":"insider"},{"id":4197461,"accession":"0001062993-25-008341","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-008341","line_url":"/filing/0001062993-25-008341#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Acrivon Therapeutics, Inc.","issuer_ticker":"ACRV","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":437881.0,"shares_display":"437,881","price_per_share":1.41,"price_display":"1.41","price_state":"stated","total_value":617412.21,"total_display":"617,412.21","total_whole":"617,412","shares_owned_after":3403025.0,"shares_owned_after_display":"3,403,025","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-30","filed_date":"2025-05-01","scope":"insider"},{"id":4508626,"accession":"0001062993-25-008214","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-25-008214","line_url":"/filing/0001062993-25-008214#line-3","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Acrivon Therapeutics, Inc.","issuer_ticker":"ACRV","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250000.0,"shares_display":"250,000","price_per_share":1.41,"price_display":"1.41","price_state":"stated","total_value":352500.0,"total_display":"352,500.00","total_whole":"352,500","shares_owned_after":3840906.0,"shares_owned_after_display":"3,840,906","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-29","filed_date":"2025-04-29","scope":"insider"},{"id":4508624,"accession":"0001062993-25-008214","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-25-008214","line_url":"/filing/0001062993-25-008214#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Acrivon Therapeutics, Inc.","issuer_ticker":"ACRV","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":215283.0,"shares_display":"215,283","price_per_share":1.56,"price_display":"1.56","price_state":"stated","total_value":335841.48,"total_display":"335,841.48","total_whole":"335,841","shares_owned_after":4090906.0,"shares_owned_after_display":"4,090,906","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-28","filed_date":"2025-04-29","scope":"insider"},{"id":4508620,"accession":"0001062993-25-008214","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-008214","line_url":"/filing/0001062993-25-008214#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Acrivon Therapeutics, Inc.","issuer_ticker":"ACRV","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1054669.0,"shares_display":"1,054,669","price_per_share":1.95,"price_display":"1.95","price_state":"stated","total_value":2056604.55,"total_display":"2,056,604.55","total_whole":"2,056,605","shares_owned_after":4306189.0,"shares_owned_after_display":"4,306,189","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-25","filed_date":"2025-04-29","scope":"insider"},{"id":4794357,"accession":"0001062993-25-007163","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-007163","line_url":"/filing/0001062993-25-007163#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3400000.0,"shares_display":"3,400,000","price_per_share":1.42,"price_display":"1.42","price_state":"stated","total_value":4828000.0,"total_display":"4,828,000.00","total_whole":"4,828,000","shares_owned_after":5875851.0,"shares_owned_after_display":"5,875,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-03","filed_date":"2025-04-07","scope":"insider"},{"id":4197190,"accession":"0001062993-25-003153","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-003153","line_url":"/filing/0001062993-25-003153#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Solid Biosciences Inc.","issuer_ticker":"SLDB","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; Perceptive Xontogeny Venture Fund, LP; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000000.0,"shares_display":"5,000,000","price_per_share":4.03,"price_display":"4.03","price_state":"stated","total_value":20150000.0,"total_display":"20,150,000.00","total_whole":"20,150,000","shares_owned_after":11833539.0,"shares_owned_after_display":"11,833,539","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-19","filed_date":"2025-02-21","scope":"insider"},{"id":3093509,"accession":"0001062993-24-015109","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-015109","line_url":"/filing/0001062993-24-015109#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"MeiraGTx Holdings plc","issuer_ticker":"MGTX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1250000.0,"shares_display":"1,250,000","price_per_share":4.0,"price_display":"4.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":12531103.0,"shares_owned_after_display":"12,531,103","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-12","filed_date":"2024-08-14","scope":"insider"},{"id":2313122,"accession":"0001062993-24-008378","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-008378","line_url":"/filing/0001062993-24-008378#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Acrivon Therapeutics, Inc.","issuer_ticker":"ACRV","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC","owner_display_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2353000.0,"shares_display":"2,353,000","price_per_share":8.5,"price_display":"8.50","price_state":"stated","total_value":20000500.0,"total_display":"20,000,500.00","total_whole":"20,000,500","shares_owned_after":5360858.0,"shares_owned_after_display":"5,360,858","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-11","filed_date":"2024-04-15","scope":"insider"},{"id":3153466,"accession":"0001062993-24-008171","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-24-008171","line_url":"/filing/0001062993-24-008171#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37712.0,"shares_display":"37,712","price_per_share":4.74,"price_display":"4.74","price_state":"stated","total_value":178754.88,"total_display":"178,754.88","total_whole":"178,755","shares_owned_after":9275851.0,"shares_owned_after_display":"9,275,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-05","filed_date":"2024-04-08","scope":"insider"},{"id":3153465,"accession":"0001062993-24-008171","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-008171","line_url":"/filing/0001062993-24-008171#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":140281.0,"shares_display":"140,281","price_per_share":4.67,"price_display":"4.67","price_state":"stated","total_value":655112.27,"total_display":"655,112.27","total_whole":"655,112","shares_owned_after":9238139.0,"shares_owned_after_display":"9,238,139","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-04","filed_date":"2024-04-08","scope":"insider"},{"id":3230312,"accession":"0001062993-24-007959","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-24-007959","line_url":"/filing/0001062993-24-007959#line-3","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":309847.0,"shares_display":"309,847","price_per_share":4.09,"price_display":"4.09","price_state":"stated","total_value":1267274.23,"total_display":"1,267,274.23","total_whole":"1,267,274","shares_owned_after":9097858.0,"shares_owned_after_display":"9,097,858","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-03","filed_date":"2024-04-03","scope":"insider"},{"id":3230303,"accession":"0001062993-24-007959","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-24-007959","line_url":"/filing/0001062993-24-007959#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":186051.0,"shares_display":"186,051","price_per_share":3.44,"price_display":"3.44","price_state":"stated","total_value":640015.44,"total_display":"640,015.44","total_whole":"640,015","shares_owned_after":8788011.0,"shares_owned_after_display":"8,788,011","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-03","scope":"insider"},{"id":3230294,"accession":"0001062993-24-007959","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-007959","line_url":"/filing/0001062993-24-007959#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8374.0,"shares_display":"8,374","price_per_share":3.25,"price_display":"3.25","price_state":"stated","total_value":27215.5,"total_display":"27,215.50","total_whole":"27,216","shares_owned_after":8601960.0,"shares_owned_after_display":"8,601,960","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-01","filed_date":"2024-04-03","scope":"insider"},{"id":2751733,"accession":"0001062993-24-001979","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-001979","line_url":"/filing/0001062993-24-001979#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Astria Therapeutics, Inc.","issuer_ticker":"ATXS","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"Perceptive Xontogeny Venture Fund, LP; PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"Perceptive Xontogeny Venture Fund, LP","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2481350.0,"shares_display":"2,481,350","price_per_share":12.09,"price_display":"12.09","price_state":"stated","total_value":29999521.5,"total_display":"29,999,521.50","total_whole":"29,999,522","shares_owned_after":4873721.0,"shares_owned_after_display":"4,873,721","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-05","scope":"insider"},{"id":2835326,"accession":"0001062993-24-000843","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-000843","line_url":"/filing/0001062993-24-000843#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Solid Biosciences Inc.","issuer_ticker":"SLDB","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; Perceptive Xontogeny Venture Fund, LP; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3410713.0,"shares_display":"3,410,713","price_per_share":5.53,"price_display":"5.53","price_state":"stated","total_value":18861242.89,"total_display":"18,861,242.89","total_whole":"18,861,243","shares_owned_after":6833539.0,"shares_owned_after_display":"6,833,539","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-11","filed_date":"2024-01-12","scope":"insider"},{"id":8579129,"accession":"0001062993-23-023292","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-023292","line_url":"/filing/0001062993-23-023292#line-3","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":115774.0,"shares_display":"115,774","price_per_share":7.24,"price_display":"7.24","price_state":"stated","total_value":838203.76,"total_display":"838,203.76","total_whole":"838,204","shares_owned_after":7099182.0,"shares_owned_after_display":"7,099,182","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-29","filed_date":"2023-12-29","scope":"insider"},{"id":8579118,"accession":"0001062993-23-023291","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-023291","line_url":"/filing/0001062993-23-023291#line-3","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":163954.0,"shares_display":"163,954","price_per_share":2.38,"price_display":"2.38","price_state":"stated","total_value":390210.52,"total_display":"390,210.52","total_whole":"390,211","shares_owned_after":5402964.0,"shares_owned_after_display":"5,402,964","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-29","filed_date":"2023-12-29","scope":"insider"},{"id":8579126,"accession":"0001062993-23-023292","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-023292","line_url":"/filing/0001062993-23-023292#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":126116.0,"shares_display":"126,116","price_per_share":7.08,"price_display":"7.08","price_state":"stated","total_value":892901.28,"total_display":"892,901.28","total_whole":"892,901","shares_owned_after":6983408.0,"shares_owned_after_display":"6,983,408","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-28","filed_date":"2023-12-29","scope":"insider"},{"id":8579114,"accession":"0001062993-23-023291","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-023291","line_url":"/filing/0001062993-23-023291#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":409598.0,"shares_display":"409,598","price_per_share":2.44,"price_display":"2.44","price_state":"stated","total_value":999419.12,"total_display":"999,419.12","total_whole":"999,419","shares_owned_after":5239010.0,"shares_owned_after_display":"5,239,010","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-28","filed_date":"2023-12-29","scope":"insider"},{"id":8579123,"accession":"0001062993-23-023292","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-023292","line_url":"/filing/0001062993-23-023292#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":79726.0,"shares_display":"79,726","price_per_share":7.2,"price_display":"7.20","price_state":"stated","total_value":574027.2,"total_display":"574,027.20","total_whole":"574,027","shares_owned_after":6857292.0,"shares_owned_after_display":"6,857,292","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-27","filed_date":"2023-12-29","scope":"insider"},{"id":8579108,"accession":"0001062993-23-023291","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-023291","line_url":"/filing/0001062993-23-023291#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Athira Pharma, Inc.","issuer_ticker":"ATHA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":32134.0,"shares_display":"32,134","price_per_share":2.28,"price_display":"2.28","price_state":"stated","total_value":73265.52,"total_display":"73,265.52","total_whole":"73,266","shares_owned_after":4829412.0,"shares_owned_after_display":"4,829,412","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-27","filed_date":"2023-12-29","scope":"insider"},{"id":8424383,"accession":"0000899243-23-020691","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-020691","line_url":"/filing/0000899243-23-020691#line-3","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":54652.0,"shares_display":"54,652","price_per_share":6.49,"price_display":"6.49","price_state":"stated","total_value":354691.48,"total_display":"354,691.48","total_whole":"354,691","shares_owned_after":6777566.0,"shares_owned_after_display":"6,777,566","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-26","filed_date":"2023-12-26","scope":"insider"},{"id":8424379,"accession":"0000899243-23-020691","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-020691","line_url":"/filing/0000899243-23-020691#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":6.67,"price_display":"6.67","price_state":"stated","total_value":1667500.0,"total_display":"1,667,500.00","total_whole":"1,667,500","shares_owned_after":6722914.0,"shares_owned_after_display":"6,722,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-22","filed_date":"2023-12-26","scope":"insider"},{"id":8424374,"accession":"0000899243-23-020691","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-020691","line_url":"/filing/0000899243-23-020691#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":6.17,"price_display":"6.17","price_state":"stated","total_value":1234000.0,"total_display":"1,234,000.00","total_whole":"1,234,000","shares_owned_after":6472914.0,"shares_owned_after_display":"6,472,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-21","filed_date":"2023-12-26","scope":"insider"},{"id":8402719,"accession":"0001062993-23-023077","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-023077","line_url":"/filing/0001062993-23-023077#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Astria Therapeutics, Inc.","issuer_ticker":"ATXS","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; EDELMAN JOSEPH; Perceptive Xontogeny Venture Fund, LP","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":740000.0,"shares_display":"740,000","price_per_share":6.2,"price_display":"6.20","price_state":"stated","total_value":4588000.0,"total_display":"4,588,000.00","total_whole":"4,588,000","shares_owned_after":2392371.0,"shares_owned_after_display":"2,392,371","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-21","filed_date":"2023-12-22","scope":"insider"},{"id":8402704,"accession":"0001062993-23-022861","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-022861","line_url":"/filing/0001062993-23-022861#line-3","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":277008.0,"shares_display":"277,008","price_per_share":5.36,"price_display":"5.36","price_state":"stated","total_value":1484762.88,"total_display":"1,484,762.88","total_whole":"1,484,763","shares_owned_after":6272914.0,"shares_owned_after_display":"6,272,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-19","filed_date":"2023-12-19","scope":"insider"},{"id":8402698,"accession":"0001062993-23-022861","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-022861","line_url":"/filing/0001062993-23-022861#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":456923.0,"shares_display":"456,923","price_per_share":5.41,"price_display":"5.41","price_state":"stated","total_value":2471953.43,"total_display":"2,471,953.43","total_whole":"2,471,953","shares_owned_after":5995906.0,"shares_owned_after_display":"5,995,906","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2023-12-19","scope":"insider"},{"id":8402694,"accession":"0001062993-23-022861","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-022861","line_url":"/filing/0001062993-23-022861#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Verrica Pharmaceuticals Inc.","issuer_ticker":"VRCA","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"PERCEPTIVE ADVISORS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":5.97,"price_display":"5.97","price_state":"stated","total_value":2985000.0,"total_display":"2,985,000.00","total_whole":"2,985,000","shares_owned_after":5538983.0,"shares_owned_after_display":"5,538,983","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-15","filed_date":"2023-12-19","scope":"insider"},{"id":8725605,"accession":"0001062993-23-020811","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-020811","line_url":"/filing/0001062993-23-020811","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"CARGO Therapeutics, Inc.","issuer_ticker":"CRGX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive Xontogeny Venture Fund II, LP; PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":666666.0,"shares_display":"666,666","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":2912835.0,"shares_owned_after_display":"2,912,835","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-14","filed_date":"2023-11-14","scope":"insider","n_lines":2},{"id":8284405,"accession":"0001062993-23-019546","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-019546","line_url":"/filing/0001062993-23-019546#line-2","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":306499.0,"shares_display":"306,499","price_per_share":1.74,"price_display":"1.74","price_state":"stated","total_value":533308.26,"total_display":"533,308.26","total_whole":"533,308","shares_owned_after":8593586.0,"shares_owned_after_display":"8,593,586","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-10-18","filed_date":"2023-10-18","scope":"insider"},{"id":8284401,"accession":"0001062993-23-019546","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-019546","line_url":"/filing/0001062993-23-019546#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"EDELMAN JOSEPH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2450000.0,"shares_display":"2,450,000","price_per_share":1.6,"price_display":"1.60","price_state":"stated","total_value":3920000.0,"total_display":"3,920,000.00","total_whole":"3,920,000","shares_owned_after":8900085.0,"shares_owned_after_display":"8,900,085","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-10-16","filed_date":"2023-10-18","scope":"insider"},{"id":8219034,"accession":"0001062993-23-019533","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-019533","line_url":"/filing/0001062993-23-019533","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Astria Therapeutics, Inc.","issuer_ticker":"ATXS","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"Perceptive Xontogeny Venture Fund, LP; EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_display_name":"Perceptive Xontogeny Venture Fund, LP","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1074608.0,"shares_display":"1,074,608","price_per_share":6.514,"price_display":"6.51","price_state":"stated","total_value":6999996.512,"total_display":"6,999,996.51","total_whole":"6,999,997","shares_owned_after":1652371.0,"shares_owned_after_display":"1,652,371","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-10-16","filed_date":"2023-10-18","scope":"insider","n_lines":2},{"id":7840274,"accession":"0001062993-23-019470","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-019470","line_url":"/filing/0001062993-23-019470#line-1","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"Cerevel Therapeutics Holdings, Inc.","issuer_ticker":"CERE","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":876808.0,"shares_display":"876,808","price_per_share":22.81,"price_display":"22.81","price_state":"stated","total_value":19999990.48,"total_display":"19,999,990.48","total_whole":"19,999,990","shares_owned_after":10794876.0,"shares_owned_after_display":"10,794,876","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-10-16","filed_date":"2023-10-17","scope":"insider"},{"id":8110957,"accession":"0001062993-23-018574","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001062993-23-018574","line_url":"/filing/0001062993-23-018574#line-15","is_derivative":false,"issuer_cik":"0001164426","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001164426","owner_cik":null,"owner_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; PERCEPTIVE ADVISORS LLC; EDELMAN JOSEPH","owner_display_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":3074542.0,"shares_owned_after_display":"3,074,542","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-28","filed_date":"2023-09-28","scope":"insider"}],"collapsed":true,"next_cursor":"2023-09-28|8110957","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001327273","name":"Lyra Therapeutics, Inc.","url":"/issuer/0001327273","role":"Ten percent owner","n_filings":5,"first_seen":"2020-05-29","last_seen":"2025-11-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001814114","name":"Orchestra BioMed Holdings, Inc.","url":"/issuer/0001814114","role":"Ten percent owner","n_filings":1,"first_seen":"2025-08-05","last_seen":"2025-08-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001781174","name":"Acrivon Therapeutics, Inc.","url":"/issuer/0001781174","role":"Ten percent owner","n_filings":3,"first_seen":"2024-04-15","last_seen":"2025-05-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001341235","name":"Aldeyra Therapeutics, Inc.","url":"/issuer/0001341235","role":"Ten percent owner","n_filings":25,"first_seen":"2015-10-22","last_seen":"2025-04-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001707502","name":"Solid Biosciences Inc.","url":"/issuer/0001707502","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2018-01-30","last_seen":"2025-02-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001735438","name":"MeiraGTx Holdings plc","url":"/issuer/0001735438","role":"Director, Ten percent owner","n_filings":6,"first_seen":"2018-06-12","last_seen":"2024-08-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001454789","name":"Astria Therapeutics, Inc.","url":"/issuer/0001454789","role":"Director","n_filings":4,"first_seen":"2022-12-21","last_seen":"2024-02-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001620463","name":"Athira Pharma, Inc.","url":"/issuer/0001620463","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2020-09-22","last_seen":"2023-12-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001660334","name":"Verrica Pharmaceuticals Inc.","url":"/issuer/0001660334","role":"Ten percent owner","n_filings":5,"first_seen":"2018-08-01","last_seen":"2023-12-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001966494","name":"CARGO Therapeutics, Inc.","url":"/issuer/0001966494","role":"Other","n_filings":1,"first_seen":"2023-11-14","last_seen":"2023-11-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001805387","name":"Cerevel Therapeutics Holdings, Inc.","url":"/issuer/0001805387","role":"Director","n_filings":7,"first_seen":"2020-10-22","last_seen":"2023-10-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001484565","name":"SOLENO THERAPEUTICS INC","url":"/issuer/0001484565","role":"Ten percent owner","n_filings":5,"first_seen":"2023-05-23","last_seen":"2023-09-28"},{"type":"issuer","type_label":"ISSUER","cik":"0000764195","name":"VBI Vaccines Inc/BC","url":"/issuer/0000764195","role":"Ten percent owner","n_filings":10,"first_seen":"2017-10-30","last_seen":"2023-04-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001596946","name":"Quotient Ltd","url":"/issuer/0001596946","role":"Ten percent owner","n_filings":5,"first_seen":"2018-05-24","last_seen":"2022-11-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001322505","name":"ALBIREO PHARMA, INC.","url":"/issuer/0001322505","role":"Ten percent owner","n_filings":4,"first_seen":"2018-01-25","last_seen":"2022-10-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001831283","name":"LianBio","url":"/issuer/0001831283","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2021-11-03","last_seen":"2022-08-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001658247","name":"Crinetics Pharmaceuticals, Inc.","url":"/issuer/0001658247","role":"Director, Ten percent owner","n_filings":6,"first_seen":"2018-07-20","last_seen":"2022-04-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001808805","name":"Nautilus Biotechnology, Inc.","url":"/issuer/0001808805","role":"Director, Ten percent owner, Other","n_filings":4,"first_seen":"2021-05-24","last_seen":"2021-12-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001261249","name":"AGILE THERAPEUTICS INC","url":"/issuer/0001261249","role":"Ten percent owner, Other","n_filings":7,"first_seen":"2018-07-26","last_seen":"2021-10-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001615055","name":"IsoPlexis Corp","url":"/issuer/0001615055","role":"Ten percent owner","n_filings":1,"first_seen":"2021-10-14","last_seen":"2021-10-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001724979","name":"Rain Therapeutics Inc.","url":"/issuer/0001724979","role":"Ten percent owner","n_filings":2,"first_seen":"2021-04-27","last_seen":"2021-10-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001368514","name":"ADMA BIOLOGICS, INC.","url":"/issuer/0001368514","role":"Ten percent owner","n_filings":7,"first_seen":"2019-05-23","last_seen":"2021-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001566044","name":"VYNE Therapeutics Inc.","url":"/issuer/0001566044","role":"Ten percent owner","n_filings":6,"first_seen":"2020-06-11","last_seen":"2021-08-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001718852","name":"Prometheus Biosciences, Inc.","url":"/issuer/0001718852","role":"Ten percent owner","n_filings":1,"first_seen":"2021-03-16","last_seen":"2021-03-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001785345","name":"Landos Biopharma, Inc.","url":"/issuer/0001785345","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-02-08","last_seen":"2021-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001178253","name":"SCYNEXIS INC","url":"/issuer/0001178253","role":"Ten percent owner","n_filings":1,"first_seen":"2021-01-26","last_seen":"2021-01-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001686850","name":"Motus GI Holdings, Inc.","url":"/issuer/0001686850","role":"Ten percent owner","n_filings":4,"first_seen":"2018-02-21","last_seen":"2021-01-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001300699","name":"Athenex, Inc.","url":"/issuer/0001300699","role":"Ten percent owner","n_filings":14,"first_seen":"2019-05-08","last_seen":"2020-09-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001509745","name":"LEAP THERAPEUTICS, INC.","url":"/issuer/0001509745","role":"Ten percent owner","n_filings":1,"first_seen":"2020-06-24","last_seen":"2020-06-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001557142","name":"Kadmon Holdings, Inc.","url":"/issuer/0001557142","role":"Ten percent owner","n_filings":1,"first_seen":"2019-11-18","last_seen":"2019-11-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001685071","name":"Dova Pharmaceuticals Inc.","url":"/issuer/0001685071","role":"Ten percent owner","n_filings":10,"first_seen":"2018-06-06","last_seen":"2019-07-11"},{"type":"issuer","type_label":"ISSUER","cik":"0000920465","name":"LA JOLLA PHARMACEUTICAL CO","url":"/issuer/0000920465","role":"Ten percent owner","n_filings":4,"first_seen":"2018-02-15","last_seen":"2019-01-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001594337","name":"Corium International, Inc.","url":"/issuer/0001594337","role":"Ten percent owner","n_filings":4,"first_seen":"2017-05-25","last_seen":"2018-10-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001178879","name":"AMICUS THERAPEUTICS INC","url":"/issuer/0001178879","role":"Ten percent owner, Other","n_filings":17,"first_seen":"2014-07-01","last_seen":"2018-10-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001375151","name":"ZOGENIX, INC.","url":"/issuer/0001375151","role":"Ten percent owner","n_filings":4,"first_seen":"2017-07-05","last_seen":"2018-08-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001629137","name":"Global Blood Therapeutics, Inc.","url":"/issuer/0001629137","role":"Ten percent owner","n_filings":1,"first_seen":"2017-12-19","last_seen":"2017-12-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001513818","name":"Versartis, Inc.","url":"/issuer/0001513818","role":"Ten percent owner","n_filings":7,"first_seen":"2016-12-30","last_seen":"2017-09-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001427925","name":"ACELRX PHARMACEUTICALS INC","url":"/issuer/0001427925","role":"Ten percent owner","n_filings":10,"first_seen":"2013-07-24","last_seen":"2017-06-21"},{"type":"issuer","type_label":"ISSUER","cik":"0000704159","name":"VBI VACCINES INC.","url":"/issuer/0000704159","role":"Ten percent owner","n_filings":3,"first_seen":"2015-08-18","last_seen":"2017-03-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001338042","name":"Aegerion Pharmaceuticals, Inc.","url":"/issuer/0001338042","role":"Ten percent owner","n_filings":8,"first_seen":"2012-12-03","last_seen":"2013-09-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001249675","retrieved_at":"2026-08-27T05:37:59+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}